Drugs Made In America Acquisition II Corp. 10-K Annual Report: Business Strategy, Acquisition Focus, and Management Overview

Drugs Made In America Acquisition II Corp. 2025 Annual Report: Key Takeaways for Investors

Introduction

Drugs Made In America Acquisition II Corp. (“the Company”) is a blank check company incorporated in the Cayman Islands, primarily established to facilitate a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses. As of December 31, 2025, the Company has not yet engaged in any business operations or generated revenue and is classified as a “shell company.”

Key Points from the Annual Report

Recent Developments

Sponsor Withdrawal: After the Company’s IPO on September 26, 2025, the Sponsor withdrew a total of \$1,345,844 from the Company’s working capital account. This withdrawal was subsequently addressed, but there remains an outstanding balance due from the Sponsor, which has been fully reserved as a current expected credit loss.
Convertible Note Issuance: On March 30, 2026, the Company entered into a \$300,000 interim convertible note with an investor. This note matures nine months from issuance (unless converted earlier) and does not bear interest. Upon consummation of a business combination, the note can be converted into shares of the combined entity at a 35% discount to market price—a potentially dilutive and price-sensitive event for shareholders.

Business Strategy

The Company’s target sector is the pharmaceutical industry, with management focusing on sourcing and evaluating acquisition targets within this space.
Key acquisition criteria include:
- Defensible and established business models with sustainable competitive advantages
- Multiple avenues for long-term growth, both organic and inorganic
- A sustainable financial profile, emphasizing stable free cash-flow and minimal reliance on leverage
- Compelling value proposition in relation to peers, aiming for attractive risk-adjusted returns
- Targets that would benefit from going public and accessing public markets
The Company may structure its business combination to acquire less than 100% but at least 50% of a target, ensuring control and compliance with the Investment Company Act.

Redemption and Shareholder Protections

All public shareholders will have the right to redeem their shares in connection with the completion of the Company’s initial business combination, either via a general meeting or a tender offer, depending on the transaction structure.
If the Company fails to complete a business combination within the prescribed window, it will cease operations and liquidate, redeeming public shares at the trust account value.

Financial Position

As of December 31, 2025, the Company had only \$223 in cash and a working capital deficit of \$274,827, highlighting a significant need to complete a business combination or secure additional financing.
The Company’s trust account held \$500,000,000 in proceeds from its IPO and private placement, invested in U.S. government securities or qualifying money market funds.
Funds available for a business combination are estimated at \$482,500,000, assuming no share redemptions and after paying deferred underwriting fees of up to \$17,500,000. The Company may use cash, equity, debt, or a combination thereof to complete a business combination.
The Company expects to incur significant professional and transaction costs as it pursues a business combination.

Related Party Transactions and Controls

The Sponsor had previously issued an unsecured promissory note for up to \$325,000, which has been fully repaid. Borrowings under this note are no longer available.
Advisory services were provided by a related party (husband of the former CEO), but no fees were incurred in 2025 or 2024.
The Company has reported material weaknesses in its internal controls, including insufficient segregation of duties, lack of formal review for related party transactions, and inadequate written policies and procedures. These weaknesses may increase operational and reporting risks.
The Sponsor’s founder shares and private placement units are subject to transfer restrictions for at least six months after the business combination or until the share price exceeds \$12.50 for 20 out of 30 trading days.
As of December 31, 2025, the Sponsor owes the Company \$812,113, which has been fully reserved due to anticipated non-recoverability.

Market Information

The Company’s units, ordinary shares, and rights are listed on Nasdaq under the symbols “DMIIU”, “DMII”, and “DMIIR”, respectively.
As of April 15, 2026, the Company had 63,700,000 ordinary shares outstanding (inclusive of shares in units).

Competition

The Company faces intense competition from other blank check companies, private equity funds, and strategic acquirers. Many competitors possess greater resources, which may limit the Company’s ability to secure attractive acquisition targets.
The obligation to redeem shares or pay cash for shares upon shareholder approval of a business combination may further reduce available resources and competitive positioning.

Risk Factors & Shareholder Considerations

The Company is classified as an “emerging growth company,” a “smaller reporting company,” and a “shell company.” It has not reported any cybersecurity incidents since its IPO.
There are no unregistered sales of securities, no equity compensation plans, and no declared dividends. The Company does not anticipate declaring dividends in the foreseeable future.
Shareholders should carefully monitor the Company’s progress toward a business combination, the terms of any convertible instruments and potential dilution, ongoing sponsor-related party balances, and the material weaknesses in internal controls.
Failure to complete a business combination within the required timeframe will result in liquidation and return of funds to shareholders at trust value, which may differ from market value.
The \$300,000 convertible note at a 35% discount to market price upon business combination could be highly dilutive and is a price-sensitive event for existing shareholders.

Conclusion

The Company is at a critical juncture as it seeks an initial business combination. Its substantial trust assets are offset by minimal operational cash, working capital deficit, and outstanding sponsor receivable now fully reserved as a credit loss. The new convertible note adds potential dilution risk. Material weaknesses in internal controls and related party activity pose additional risks. Investors should closely monitor developments given the potential for significant share price movement around business combination announcements, capital raises, or failure to complete a transaction.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filings, consult professional advisors, and consider their own circumstances before making investment decisions. The information herein is based on available data as of the date of the referenced annual report and may be subject to change.